| Literature DB >> 22001392 |
Tasneem Motiwala1, Nicola Zanesi, Jharna Datta, Satavisha Roy, Huban Kutay, Allyn M Checovich, Mohamed Kaou, Yiming Zhong, Amy J Johnson, David M Lucas, Nyla A Heerema, John Hagan, Xiaokui Mo, David Jarjoura, John C Byrd, Carlo M Croce, Samson T Jacob.
Abstract
We previously demonstrated that the gene encoding PTPROt, the truncated form of protein tyrosine phosphatase receptor type O expressed predominantly in hematopoietic cells, is a candidate tumor suppressor and is down-regulated in chronic lymphocytic leukemia (CLL). Here, we show that PTPROt expression is significantly reduced in CD19(+) spleen B cells from Eμ-T cell leukemia 1 (TCL1) transgenic mice relative to the wild-type mice. Strikingly, as much as a 60% decrease in PTPROt expression occurs at 7 weeks independently of promoter methylation. To elucidate the potential mechanism for this early suppression of PTPROt in these mice, we explored the role of activating protein-1 (AP-1) in its expression. We first demonstrate that AP-1 activation by 12-O-tetradecanoylphorbol-13-acetate induces PTPROt expression with concurrent recruitment of c-fos and c-jun to its promoter. The PTPROt promoter is also responsive to over- and underexpression of AP-1, confirming the role of AP-1 in PTPROt expression. Next, we demonstrate that TCL1 can repress the PTPROt promoter by altering c-fos expression and c-jun activation state. Finally, using primary CLL cells we have shown an inverse relationship between TCL1 and PTPROt expression. These findings further substantiate the role of TCL1 in PTPROt suppression and its importance in the pathogenesis of CLL.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22001392 PMCID: PMC3234669 DOI: 10.1182/blood-2011-01-323147
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113